These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23552005)

  • 1. Unique presentations of epidermal growth factor receptor inhibitor-induced papulopustular eruption related to bacterial superinfection.
    Wiznia LE; Choi JN
    Dermatol Online J; 2013 Mar; 19(3):8. PubMed ID: 23552005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.
    Braden RL; Anadkat MJ
    Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
    Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
    Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab-induced crusted pustular eruption with patchy alopecia.
    Fischer R; Blackmon J; Rajpara A
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
    Pongpudpunth M; Demierre MF; Goldberg LJ
    J Cutan Pathol; 2009 Dec; 36(12):1303-7. PubMed ID: 19519875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
    Tohyama M; Hamada M; Harada D; Kozuki T; Nogami N; Monden N; Kajiwara T; Nishina T
    J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I; David M; Stemmer SM
    Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
    Seiverling EV; Fernanadez EM; Adams D
    J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
    Wnorowski AM; de Souza A; Chachoua A; Cohen DE
    Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.
    Toda N; Fujimoto N; Kato T; Fujii N; Nakanishi G; Nagao T; Tanaka T
    Dermatology; 2012; 225(1):18-21. PubMed ID: 22922680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption.
    Farahnik B; Kwong B; Murase J
    J Am Acad Dermatol; 2016 Nov; 75(5):e191. PubMed ID: 27745649
    [No Abstract]   [Full Text] [Related]  

  • 14. Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin.
    Akoglu G; Yavuz SO; Metin A
    Indian J Pharmacol; 2016; 48(3):324-6. PubMed ID: 27298507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature.
    Nazzaro G; Giacalone S; Bortoluzzi P; Veraldi S; Marzano AV
    Dermatol Online J; 2021 Feb; 27(2):. PubMed ID: 33818981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients.
    Bellini V; Bianchi L; Pelliccia S; Lisi P
    J Cutan Pathol; 2016 Mar; 43(3):211-8. PubMed ID: 26423594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malassezia folliculitis presented as acneiform eruption after cetuximab administration.
    Cholongitas E; Pipili C; Ioannidou D
    J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption.
    Takata T; Tarutani M; Zouboulis CC; Sano S
    J Dermatol Sci; 2012 May; 66(2):165-8. PubMed ID: 22440861
    [No Abstract]   [Full Text] [Related]  

  • 19. The Most Common Cutaneous Side Effects of Epidermal Growth Factor Receptor Inhibitors and Their Management.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2015; 23(4):282-8. PubMed ID: 26724881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
    Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
    J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.